Genetically engineered bacterium of colon bacillus for producing arabinoside-cytidine monophosphate lipoid A, and application thereof

A technology of genetically engineered bacteria and monophosphoric acid lipids, applied in the field of genetically engineered bacteria, can solve problems affecting product quality and yield, numerous steps, and difficult operations
CN102994435AInactive Publication Date: 2013-03-27JIANGNAN UNIV
1 Cites 9 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
JIANGNAN UNIV
Publication Date
2013-03-27
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a genetically engineered bacterium of a colon bacillus for producing arabinoside-cytidine monophosphate lipoid A. The genetically engineered bacterium is characterized in that a deletion mutation deactivation is carried out on lacz genes in a genome of the genetically engineered bacterium; and express exogenous pagL and lpxE and pagP genes are implanted into the lacz genes. According to the invention, the formed bacterial strain cannot produce a pathogenic bacterium and is free of the use of an inductive agent during a production process. Therefore, the genetically engineered bacterium is suitable for mass production of MPL adjuvants in earlier stages.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to a genetically engineered bacterium producing monophosphate lipid A (MPL), in particular to an Escherichia coli directly producing MPL without induction. technical background

[0002] Vaccine adjuvants can non-specifically enhance the body's immune response to antigens and improve vaccine efficiency. Aluminum adjuvant is currently recognized globally as a vaccine adjuvant widely used in humans. It is safe and reliable, and can significantly enhance humoral immune response, but its effect on cellular immunity is not ideal. Therefore, people are devoting themselves to developing more efficient and safer vaccine adjuvants. Lipid A can be recognized by Toll Like Receptor 4 (TLR-4) on the surface of host cells, and then trigger a series of physiological and biochemical reactions in the cells, producing TNF-α, IL-6, IL-8, etc. Various inflammatory cytokines. The types and quantities of cytokines mainly depend on the structure of li...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More